Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check4 days agoChange DetectedStudy location information was updated: new locations across multiple states and Ontario were added, several existing locations were removed, and the page revision now shows v3.3.3.SummaryDifference1%

- Check11 days agoChange DetectedThe page shows new update timestamps (2025-12-15 and 2025-12-12) and a current 'Last Update Posted' marker, while older timestamps (2025-09-03, 2025-09-02, 2025-06) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 on the page footer; no study details or user-facing content were modified. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed.SummaryDifference0.0%

- Check40 days agoChange DetectedThe funding-status notice banner about potential data staleness due to government funding lapses has been removed from the page. This administrative banner previously warned that information on this site may not be up to date.SummaryDifference0.3%

- Check54 days agoChange DetectedNo significant changes were detected in the Study Details page for NCT03854474. The content and layout appear unchanged aside from routine metadata such as the last update timestamp.SummaryDifference0.3%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.